Why Vir Biotechnology, Inc.’s (VIR) Stock Is Down 16.01%
As of Friday, November 13, Vir Biotechnology, Inc.’s VIR share price has dipped by 16.01%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Jenna Brashear
Jenna Brashear
Michael Rose
| Share Statistics | VIR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,434.4 | $203.5 | 52% |
|
| Shares Out (Mil) | 169.3 | 55.2 | 72% |
|
| Institutional Ownership | 94.3% | 93.3% | 64% |
|
| Float (Mil) | 141.1 | 40.4 | 67% |
|
| Beta | 1.74 | 1.05 | 87% |
|
| Avg Daily Volume (000s) | 4,583 | 569 | 91% |
|
| Price Change (52-week) |
54.0% | 38.8% | 90% |
|
| Growth | VIR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (2.1%) | 13.6% | 13% |
|
| Net Income (5yr) | (8.0%) | (10.7%) | 31% |
|
| EPS (5yr) | (4.7%) | 15.4% | 26 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.1%) | (15.7%) | 41% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 7 | |
| Current EPS | ($0.080) | ($1.011) | ($2.373) | |
| Month Ago EPS | ($0.630) | ($1.755) | ($2.487) | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.647) | ($1.780) | ($2.493) | |
| Year/Year Chg | (85.9%) | (68.0%) | (36.8%) | |
| Financials | VIR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $303 | $40 | 35% |
|
| Net Income (TTM) (Mil) | ($185) | ($44) | 7% |
|
| EPS (TTM) | ($1.185) | ($1.400) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($141) | ($35) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $49 | $-0 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $82 | $4 | 42% |
|
| Enterprise Value (Q1) (Mil) | $1,520 | $142 | 46% |
|
| Valuation | VIR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.58 | 1.96 | 49% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | VIR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (36.7%) | 67.6% | 2% |
|
| Net Margin | (61.0%) | (50.8%) | 10% |
|
| ROA | (17.3%) | (47.0%) | 21% |
|
| ROE | (21.8%) | (51.8%) | 22% |
|
| Liabilities to Assets | 19.4% | 29.6% | 12% |
|
| F-Score | 4 | 3 | 33% |
|
Vir Biotechnology, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors